Overview

A Study to Assess the Efficacy and Safety of MNK-1411 in Duchenne Muscular Dystrophy

Status:
Terminated
Trial end date:
2020-02-25
Target enrollment:
Participant gender:
Summary
This is a multicenter, double blind, placebo controlled, multiple dose study to examine the safety and efficacy of MNK-1411 in male subjects 4 to 8 years of age (inclusive) with Duchenne Muscular Dystrophy (DMD).
Phase:
Phase 2
Details
Lead Sponsor:
Mallinckrodt
Mallinckrodt ARD LLC
Treatments:
Cosyntropin